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Abstract
Background:  Since  the  publication  in  2009  of  the  Guidelines  on  the  Diagnosis  and  Treatment  of
Irritable Bowel  Syndrome  of  the  Asociación  Mexicana  de  Gastroenterología  (2009  Guidelines),
there have  been  signiﬁcant  advances  in  our  knowledge  of  the  epidemiology,  pathophysiology,
diagnosis, and  treatment  of  this  disease.
Aims:  To  present  a  consensus  review  of  the  most  current  knowledge  of  IBS,  updating  the  2009
Guidelines  by  incorporating  new  internationally  published  scientiﬁc  evidence,  with  a  special
interest in  Mexican  studies.
Methods:  The  PubMed  literature  from  January  2009  to  March  2015  was  reviewed  and  comple-
mented  through  a  manual  search.  Articles  in  English  and  Spanish  were  included  and  preference
was given  to  consensuses,  guidelines,  systematic  reviews,  and  meta-analyses.  Statements
referring  to  the  different  aspects  of  the  disease  were  formulated  and  voted  upon  by  24  gastroen-
terologists  employing  the  Delphi  method.  Once  a  consensus  on  each  statement  was  reached,
the quality  of  evidence  and  strength  of  recommendation  were  determined  through  the  GRADE
system.
Results: Forty-eight  statements  were  formulated,  updating  the  information  on  IBS  and  adding
the complementary  data  that  did  not  appear  in  the  2009  Guidelines  regarding  the  importance
of exercise  and  diet,  diagnostic  strategies,  and  current  therapy  alternatives  that  were  analyzed
with more  stringent  scientiﬁc  vigor  or  that  emerged  within  the  last  5  years.
Conclusions:  We  present  herein  a  consensus  review  of  the  most  relevant  advances  in  the  study
of IBS,  updating  and  complementing  the  2009  Guidelines.  Several  studies  conducted  in  Mexico
were included.
©  2016  Asociacio´n  Mexicana  de  Gastroenterolog´ıa.  Published  by  Masson  Doyma  Me´xico  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Consenso  mexicano  sobre  el  síndrome  de  intestino  irritable
Resumen
Antecedentes:  Desde  la  publicación  de  las  guías  de  diagnóstico  y  tratamiento  del  síndrome  del
intestino irritable  (SII)  de  la  Asociación  Mexicana  de  Gastroenterología  en  el  2009  (Guías  2009)
se han  producido  avances  signiﬁcativos  en  el  conocimiento  de  la  epidemiología,  ﬁsiopatogenia,
diagnóstico  y  tratamiento  de  esta  enfermedad.
Objetivos:  Presentar  una  revisión  consensuada  del  estado  actual  de  los  conocimientos  sobre  el
SII que  actualicen  las  Guías  2009,  integrando  las  nuevas  evidencias  cientíﬁcas  publicadas  a  nivel
mundial con  énfasis  en  estudios  realizados  en  México.
Métodos:  Se  realizó  una  revisión  de  la  bibliografía  en  PubMed  de  enero  del  2009  a  marzo  del
2015, que  se  complementó  en  forma  manual.  Se  incluyeron  todas  las  publicaciones  en  inglés
y espan˜ol,  con  preferencia  por  los  consensos,  guías,  revisiones  sistemáticas  y  metaanálisis.  Se
generaron enunciados  en  los  diferentes  aspectos  de  la  enfermedad  que  fueron  votados  por  24
gastroenterólogos  con  el  método  Delphi.  Una  vez  consensuado  cada  enunciado,  se  caliﬁcó  el
nivel de  la  evidencia  y  se  otorgó  la  fuerza  de  la  recomendación  utilizando  el  sistema  GRADE.
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Resultados:  Se  generaron  48  enunciados  que  actualizaron  la  información  sobre  el  SII  y  comple-
mentaron  la  información  que  no  había  sido  incluida  en  las  Guías  2009  con  referencia  al  papel  del
ejercicio y  la  dieta,  las  estrategias  diagnósticas,  así  como  alternativas  de  tratamiento  existentes
que fueron  evaluadas  con  mayor  rigor  o  que  surgieron  en  los  5  últimos  an˜os.
Conclusiones:  Presentamos  una  revisión  consensuada  de  los  progresos  más  relevantes  en  el  SII,
que actualizan  y  complementan  las  Guías  2009.  Se  incluyen  diversos  estudios  realizados  en
México.
© 2016  Asociacio´n  Mexicana  de  Gastroenterolog´ıa.  Publicado  por  Masson  Doyma  Me´xico  S.A.
Este es  un  art´ıculo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Irritable  bowel  syndrome  (IBS)  is  the  most  frequently  diag-
nosed  gastrointestinal  disorder  in  clinical  practice.1 It  is
a  functional  disorder  characterized  by  abdominal  pain  or
discomfort  that  is  associated  with  bowel  habit  alterations
and  other  gastrointestinal  symptoms,  such  as  bloating  and
a  sensation  of  abdominal  inﬂammation,  incomplete  bowel
movement,  urgency,  straining,  and  tenesmus.2--4 It  is  a  clin-
ical  condition  whose  symptoms  cannot  be  explained  by
organic,  metabolic,  or  underlying  infectious  causes.
In  2009  the  Asociación  Mexicana  de  Gastroenterología
brought  together  a  group  of  gastroenterologists  that  for-
mulated  the  Guidelines  on  the  Diagnosis  and  Treatment  of
IBS.2--4 One  year  later,  under  the  auspices  of  the  same  Asso-
ciation,  a  broad  review  of  the  pharmacologic  treatment  of
IBS  was  published.5 Since  then,  there  have  been  signiﬁcant
advances  in  different  aspects  of  the  disease,  including  epi-
demiology,  pathophysiology,  the  role  of  the  microbiota  and
diet,  the  use  of  probiotics,  novelties  in  the  use  of  diag-
nostic  biomarkers,  quality  studies  on  the  effectiveness  of
combined  drugs  and  medications,  as  well  as  new  drugs,
some  of  which  have  recently  arrived  in  Mexico.  Innovative
themes  have  also  emerged  in  the  international  literature,
such  as  fecal  microbiota  transplantation.  All  these  advances
justify  the  elaboration  of  a  document  complementing  the
2009  Diagnosis  and  Treatment  Guidelines.  In  January  of
2015,  the  Asociación  Mexicana  de  Gastroenterología  sum-
moned  a  group  of  experts  to  carry  out  a  review  of  the
advances  made  in  relation  to  different  aspects  of  IBS,
evaluate  the  evidence,  reach  a  quality  consensus,  and  for-
mulate  statements  for  understanding  the  current  status  of
IBS.
The  aim  of  the  2015  Mexican  Consensus  on  IBS  is  to
present  a  consensus  review  of  the  current  status  of  IBS  to
bring  the  2009  Guidelines  on  the  Diagnosis  and  Treatment  of
IBS  up-to-date  by  incorporating  the  new  internationally  pub-
lished  scientiﬁc  evidence,  with  a  special  interest  in  studies
conducted  in  Mexico.
MethodsThe  Delphi  method  was  used  to  prepare  this  consensus.6
The  consensus  coordinators  found  the  published  articles
to  be  reviewed  through  the  search  words  ‘‘irritable
a
m
s
oowel  syndrome’’  and  ‘‘IBS’’  combined  with  the  fol-
owing  terms:  ‘‘diagnosis’’  ‘‘diet’’,  ‘‘epidemiology’’,
‘fecal  transplant’’,  ‘‘FODMAP’’,  ‘‘gluten’’,  ‘‘guidelines’’,
‘hypnotherapy’’,  ‘‘hypnosis’’,  ‘‘incidence’’,  ‘‘meta-
nalysis’’,  ‘‘microbiota’’,  ‘‘prevalence’’,  ‘‘probiotic’’,
‘psychological’’,  ‘‘review,  ‘‘symptoms’’,  ‘‘therapy’’,
‘management’’  and  ‘‘treatment’’, as  well  as  the  equiv-
lent  terms  in  Spanish.  The  search  was  conducted  using
he  PubMed  database  and  included  articles  in  both  English
nd  Spanish  that  were  published  within  the  time  frame
f  January  2009  to  March  2015.  Preference  was  given  to
onsensuses,  guidelines,  systematic  reviews,  and  meta-
nalyses,  but  was  not  limited  to  these  types  of  articles.
omplementary  online  and  manual  searches  were  also
arried  out  using  the  archives  of  the  Revista  de  Gastroen-
erología  de  México  and  any  of  the  publications  that  the
oordinators  felt  were  relevant  up  to  March  2015.
After  the  review  of  each  theme,  a series  of  state-
ents  were  formulated  that  covered  the  main  aspects  of
he  disease.  These  were  then  sent  to  all  the  2015  IBS
onsensus  panel  members  for  the  ﬁrst  anonymous  voting
rocess  carried  out  electronically,  voting  ‘‘in  agreement’’
r  ‘‘in  disagreement’’  for  each  statement.  When  agree-
ent  equal  to  or  greater  than  75%  was  reached,  it  was
etermined  that  the  statement  could  remain  unchanged,
assing  to  the  next  round  of  voting.  Statements  with  dis-
greement  of  75%  or  higher  were  eliminated  from  the
onsensus.  The  statements  with  less  than  75%  agreement
r  disagreement  were  restated  by  the  coordinator  of  each
orking  group,  taking  into  account  the  comments  of  the
articipants.  Three  rounds  of  voting  were  carried  out
y  email  and  an  in-person  vote  was  held  at  Boca  del
ío  (Veracruz),  in  March  2015.  In  the  ﬁnal  voting  pro-
ess,  the  votes  were  cast  using  a  6-point  scale:  A)  in
omplete  agreement;  B)  in  agreement,  with  minor  reser-
ations;  C)  in  agreement,  with  major  reservations;  D)  in
isagreement,  with  major  reservations;  E)  in  disagreement,
ith  minor  reservations;  or  F)  in  complete  disagree-
ent.  In  the  present  review,  consensus  was  considered
hen  67%  of  the  participants  or  more  were  in  agreement
A,  B,  or  C).
Once  the  ﬁnal  consensus  statements  were  determined,
he  coordinators  established  the  level  of  evidence  that  sup-
orted  each  statement  and  a recommendation  grade  when
ppropriate,  using  the  Grading  of  Recommendations,  Assess-
ent,  Development  and  Evaluation  (GRADE)  system.7 This
ystem  came  about  through  an  international  initiative  to
ptimize  the  evaluation  of  quality  of  evidence  and  the
152  
Table  1  GRADE  system:  Classiﬁcation  of  the  quality  of  evi-
dence  and  the  strength  of  recommendation.
Quality  of  evidence  Code
High  A
Moderate  B
Low C
Very low  D
Strength  of  recommendation  Code
Strong,  in  favor  of  the  intervention 1
Weak,  in  favor  of  the  intervention 2
Weak,  against  the  intervention 2
Strong,  against  the  intervention  1
Modiﬁed from the On˜ate-Ocan˜a et al.8 and Sanabria et al.9 ref-
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rading  of  strength  of  recommendation,  in  an  effort  to  over-
ome  the  limitations  of  previous  systems.  In  the  GRADE
ystem,  the  quality  of  evidence  is  not  rated  solely  on  study
esign  or  methodology,  but  in  relation  to  a  clearly  posed
uestion  about  a  clearly  formulated  outcome  measure.8
ven  though,  in  general,  the  best  evidence  comes  from
ontrolled  clinical  trials  and  their  meta-analyses,  as  well
s  from  high  quality  cohort  studies,  whereas  lower  qual-
ty  evidence  comes  from  case-control  studies,  case  series,
ross-sectional  surveys,  and  expert  opinions,  the  GRADE  sys-
em  classiﬁes  the  quality  of  evidence  based  on  the  design
sed  to  answer  the  speciﬁc  question  that  has  been  posed  a
riori.8,9 In  such  a  manner,  the  study  methodology  required
s  different,  depending  on  the  question,  and  its  quality  is
udged  according  to  the  response  to  that  question.  Thus  the
uality  of  evidence  can  be  high,  moderate,  low,  or  very  low.
t  is  deﬁned  as  ‘‘high’’,  when  more  research  will  not  mod-
fy  our  conﬁdence  in  the  estimated  effect,  ‘‘moderate’’,
hen  more  research  may  modify  our  conﬁdence  in  the  esti-
ated  effect,  ‘‘low’’  when  more  research  will  most  likely
mportantly  affect  our  conﬁdence  in  the  estimated  effect,
nd  ‘‘very  low’’  when  any  estimated  effect  is  highly  uncer-
ain.  In  addition,  the  GRADE  system  establishes  strength
f  recommendation  as  strong  or  weak,  for  or  against  the
ntervention  or  statement.  It  employs  a  code  for  the  qual-
ty  of  evidence,  using  capital  letters  followed  by  a  number
o  indicate  the  strength  of  recommendation  for  or  against
he  intervention  or  statement.8,9 Table  1  shows  the  GRADE
ystem  codes.
The  consensus  statements  by  section  are  listed  below:
eﬁnition, pathophysiology, and epidemiology
f irritable bowel syndrome in adults
rritable  bowel  syndrome  is  a  functional  disorder
haracterized  by  abdominal  pain  or  discomfort
hat is  associated  with  changes  in  bowel  movement
requency  or  appearance
BS  is  deﬁned  as  a  chronic  and  recurring  functional  disor-
er  that  is  characterized  by  abdominal  pain  or  discomfort,
s
a
l
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ssociated  with  changes  in  bowel  movement  frequency  or
ppearance.2--4,10 It  is  considered  one  of  the  most  common
unctional  disorders,  is  presently  incurable,  and  can  affect
atient  quality  of  life  to  varying  degrees.11
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  C1,  strong,  in  favor  of  the  statement
Level  of  agreement:  In  complete  agreement  92%.
In  agreement  with  minor  reservations:  8%.
BS  incidence  in Mexico  is  unknown  and  there  are
o reports  on  this  subject
ven  though  several  good  quality  studies  have  been  con-
ucted  in  Mexico  on  IBS  etiology,  none  of  them  establishes
he  number  of  new  cases  of  the  disease  having  emerged
t  a  given  period  of  time,  and  therefore  the  incidence
f  this  functional  disorder  in  our  country  is  presently
nknown.12--15GRADE  level  of  evidence  and  strength  of  rec-
mmendation:  D1,  strong,  in  favor  of  the  statement.
Level  of  agreement:  In  complete  agreement  100%
he  reported  prevalence  of  IBS  in  Mexico  varies
rom 4.4  to  35%
his  wide  variation  in  the  epidemiologic  results  in  Mex-
co  is  largely  explained  by  the  criteria  used  to  deﬁne  the
resence  of  IBS.  Some  studies  have  pointed  out  that  the
ome  III  questionnaires  appear  to  have  low  sensitivity  in
he  community  for  identifying  IBS  cases.15--17 In  accordance
ith  this,  Amieva-Balmori  et  al.15 reported  a  prevalence
f  4.4%  using  the  Rome  III  criteria,  whereas  prevalences
f  up  to  35%  have  been  obtained  in  studies  using  the
ome  II  criteria.12--14GRADE  level  of  evidence  and  strength
f  recommendation:  C1,  strong,  in  favor  of  the  state-
ent.
Level  of  agreement:  In  complete  agreement  96%.
In  agreement  with  minor  reservations:  4%.
here  is  a  higher  IBS  prevalence  in  women,
egardless  of  the  diagnostic  criteria  used
s  in  the  rest  of  the  world,  IBS  in  Mexico  is  more  preva-
ent  in  women,  regardless  of  the  subtype.  This  fact  has  been
onsistently  reported  in  epidemiologic  studies  conducted  in
ur  country.12--15GRADE  level  of  evidence  and  strength  of
ecommendation:  B1,  strong,  in  favor  of  the  statement.
Level  of  agreement:  In  complete  agreement  96%.
In  agreement  with  minor  reservations:  4%.
BS  has  a  more  negative  impact  on  quality  of  life  in
oung adults  than  in  older  adults
ifferent  studies  conducted  on  Mexican  patients  coincide
ith  the  fact  that  IBS  negatively  affects  quality  of  life,  when
easured  through  different  instruments.18--22 At  least  onetudy  conducted  in  the  United  States  showed  that  young
dults  with  this  functional  disorder  have  worse  quality  of
ife  than  older  adults.23 This  datum  has  not  been  reported
n  national  studies.
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GRADE  level  of  evidence  and  strength  of  recommenda-
tion:  C1,  strong,  in  favor  of  the  statement.
Level  of  agreement:  In  complete  agreement  75%.
In  agreement  with  minor  reservations  24%.
In  agreement  with  major  reservations  1%.
The  most  frequent  IBS  subtypes  in  Mexico  are
those with  a  predominance  of  constipation  and  the
mixed subtype
Studies  in  Mexico  have  found  that  the  most  frequent  subtype
of  this  disorder  is  the  one  in  which  there  is  a  predominance
of  constipation  (IBS-C),  followed  by  the  alternate  or  mixed
subtype  (IBS-M).12,13,15 Only  one  study  has  reported  a  higher
frequency  in  the  diarrhea-prominent  subtype  (IBS-D)  than  in
the  IBS-M  subtype,  but  it  still  found  the  greatest  frequency
in  IBS-C.14
GRADE  level  of  evidence  and  strength  of  recommenda-
tion:  B1,  strong,  in  favor  of  the  statement.
Level  of  agreement:  In  complete  agreement  96%.
In  agreement  with  minor  reservations  4%.
IBS  pathophysiology  is  multifactorial  and  varies
among the  affected  individuals.  At  present,  no
universal factor  has  been  established
Numerous  and  different  mechanisms  intervene  in  IBS  patho-
physiology,  among  which  are  motor  disorders,  visceral
hypersensitivity,  gut  microbiota  alterations  or  dysbio-
sis,  post-infectious  intestinal  dysfunction,  small  intestinal
bacterial  overgrowth,  low-grade  inﬂammation,  immune  reg-
ulation  alterations,  food  intolerance  and  hypersensitivity,
bile  acid  malabsorption,  and  psychosocial  factors,  but  up
to  the  present,  no  common  factor  for  all  cases  has  been
established. 24--27
GRADE  level  of  evidence  and  strength  of  recommenda-
tion:  C1,  strong,  in  favor  of  the  statement.
Level  of  agreement:  In  complete  agreement  100%.
The  ingestion  of  lactose  and  other  fermentable
oligosaccharides,  disaccharides,  monosaccharides,
and polyols  (FODMAPs)  may  be  associated  with
greater production  of  gas,  visceral
hypersensitivity,  and  perception  of  bloating,
especially  in  the  subgroup  of  patients  with
diarrhea-predominant  IBS
Some  foods  have  been  described  that  possibly  aggravate
IBS  symptoms.  A  Mexican  study  showed  that  intoler-
ance  to  fructose  may  be  responsible  for  gastrointestinal
symptoms  in  at  least  half  of  the  patients  with  IBS,  espe-
cially  in  those  with  IBS-D.28 Other  authors  report  that
lactose  intolerance  is  more  prevalent  in  patients  with
IBS-D  than  in  healthy  subjects, 29 and  that  they  also
have  greater  mucosal  immunity  activation  and  greater
visceral  hypersensitivity  after  lactose  ingestion.29,30 One
Mexican  study  found  statistically  signiﬁcant  improvement
in  3  evaluated  symptoms  (abdominal  pain,  bloating,  and
ﬂatulence)  in  the  comparison  of  pre-low-FODMAP  and  post-
low-FODMAP  diet  values.31 However,  that  study  had  the
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imitation  of  not  having  a  control  group  that  included
he  average  or  regular  diet  of  the  study  population;
nother  limitation  was  that  both  diets  did  not  have
he  same  nutritional  content.32 Those  ﬁndings  concurred
ith  other  international  studies  reporting  that  FODMAPs
ppear  to  induce  some  symptoms  in  patients  with  IBS
hrough  increased  luminal  distension  and  if  there  is  visceral
ypersensitivity.33
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  C1,  strong,  in  favor  of  the  statement.
Level  of  agreement:  In  complete  agreement  96%.
In  agreement  with  minor  reservations  4%.
he  prevalence  of  small  intestinal  bacterial
vergrowth  in  patients  with  IBS  is  quite  variable,
epending on  the  test  and  methodology  employed
he  presence  of  small  intestinal  bacterial  growth  has  been
ointed  out,  based  on  breath  tests  measuring  the  hydro-
en  in  the  exhaled  breath  of  IBS  patients.  The  reported
revalence  is  varied  and  depends  on  the  type  of  test  and
ethodology  used:  28  to  84%  with  a  lactulose  breath  test,
 to  31%  with  a  glucose  breath  test,  and  a  lower  prevalence
2  to  6%)  when  intestinal  ﬂuid  cultures  are  used.27
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  C1,  strong,  in  favor  of  the  statement.
Level  of  agreement:  In  complete  agreement  88%.
In  agreement  with  minor  reservations  8%.
In  disagreement  with  major  reservations  4%.
he  incidence  of  post-infectious  IBS  is  from  9  to
0%. The  reported  prevalence  of  post-infectious
BS varies  from  3  to  17%  and  decreases  in  the  years
ollowing  the  gastrointestinal  infection
ost-infectious  IBS  (PI-IBS)  incidence  has  been  reported  at
0%  (range  4-36%)  and  prevalence  varies  from  3  to  17%
nd  decreases  in  the  years  following  the  gastrointestinal
nfection.24,34,35 A  recently  published  systematic  review  and
eta-analysis  that  included  6  studies  determined  that  the
verall  incidence  of  PI-IBS  was  5.4%  in  patients  that  had  pre-
ented  with  traveler’s  diarrhea  compared  with  1.4%  of  the
ontrol  subjects,  and  the  overall  relative  risk  was  3.35  (95%
I:  2.22-5.05).36
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  C1,  strong,  in  favor  of  the  statement.
Level  of  agreement:  In  complete  agreement  75%.
In  agreement  with  minor  reservations  21%.
In  agreement  with  major  reservations  4%.
n  relation  to  PI-IBS,  bacterial  etiology  is  the  best
ocumented, but  viral  and  parasitic  causes  also
ppear to  be  risk  factors  for  developing  PI-IBS
I-IBS  has  been  studied  in  numerous  cohort  studies  that
onducted  follow-up  analyses  of  epidemic  outbreaks  of
acterial  gastroenteritis  and  therefore  this  etiology  is  the
est  documented.  Studies  on  acute  gastroenteritis  due  to
iruses  and  parasites  have  also  been  published,  but  these
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tudies  are  much  fewer  and  include  a  small  number  of
atients.27
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  C1,  strong,  in  favor  of  the  statement.
Level  of  agreement:  In  complete  agreement  92%.
In  agreement  with  minor  reservations  8%.
BS  has  been  associated  with  different  intestinal
nd extraintestinal  symptoms  and  syndromes
ome  community-based  surveys  have  conﬁrmed  that  IBS
requently  overlaps  with  functional  dyspepsia  and  with  gas-
roesophageal  reﬂux  symptoms,  especially  in  nonerosive
eﬂux  disease.  IBS  has  also  been  associated  with  a  variety
f  psychological  disorders,  but  the  evidence  of  an  actual
ssociation  is  less  solid.  It  has  been  suggested  that  psy-
hopathology  be  considered  a  cofactor  that,  if  present,
ill  modify  the  response  to  the  different  IBS  symptoms
n  each  individual.37 In  a  study  conducted  in  Mexico  City
tilizing  the  Rome  II  questionnaire,  the  researchers  found
hat  heartburn  and  other  reﬂux  symptoms  were  more  fre-
uent  in  patients  with  IBS  than  in  controls,  regardless  of
heir  body  mass  index.38 Another  study  also  conducted  in
ur  country  on  patients  with  IBS  showed  differences  in
ymptom  association  depending  on  the  IBS  subtype,  using
he  Rome  III  questionnaire.  Thus,  the  IBS-M  subtype  had  a
igher  association  with  symptoms  such  as  halitosis,  vom-
ting,  and  greater  intensity  early  satiety,  and  IBS-C  was
ssociated  with  straining  and  tenesmus,  whereas  IBS-D  was
ssociated  with  urgent  bowel  movements  and  daytime  or
ighttime  fecal  incontinence.39 Patients  with  inﬂammatory
owel  disease  (IBD)  have  also  been  reported  to  have  a
reater  frequency  of  symptoms  consistent  with  IBS  com-
ared  with  controls  (non-IBD  subjects),  even  among  patients
hat  appeared  to  be  in  remission.  In  addition,  IBS  symp-
oms  were  more  frequent  in  patients  with  Crohn’s  disease
han  in  those  with  ulcerative  colitis  (UC)  and  in  those  with
ctive  disease.40 These  ﬁndings  are  very  similar  to  those
hat  have  been  reported  in  patients  with  celiac  disease
CD).41
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  C1,  strong,  in  favor  of  the  statement.
Level  of  agreement:  In  complete  agreement  88%.
In  agreement  with  minor  reservations  8%.
In  agreement  with  major  reservations  4%.
rritable bowel syndrome diagnosis in adults
ymptom-based  diagnostic  criteria  enable  positive
BS diagnosis  to  be  made  in  those  patients  with  no
larm symptoms  or  risk  factors.  Nevertheless,
heir  sensitivity  and  speciﬁcity  is  variable  and
ome patients  with  organic  disease  have  diagnostic
BS criteria,  demonstrating  the  need  for  their
odiﬁcation  in  order  to  have  greater  diagnostic
ccuracy
here  is  clear  evidence  of  the  limitations  of  the
ome  clinical  criteria  in  diagnosing  IBS. 42--45 Another
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ystematic  review  that  included  studies  published  over  a
road  period  of  time  that  evaluated  the  3  versions  of  the
ome  criteria,  as  well  as  the  Manning  criteria,  found  that
he  latter  had  been  more  accurate  and  validated  more
ften,  whereas  the  Rome  III  criteria  had  not  been  vali-
ated  or  widely  adopted  in  clinical  research,  up  to  the
resent.42 Among  patients  evaluated  with  Rome  III  criteria,
.3%  were  observed  to  have  Crohn’s  disease,  6.1%  ulcer-
tive  colitis,  and  2.3%  cancer  of  the  colon.45 Fifty-nine
linicians  and  researchers  participating  in  an  international
urvey  were  asked  to  review  the  diagnostic  criteria  and
7%  stated  that  the  Rome  criteria  did  not  adequately
eﬂect  IBS  in  their  community  or  medical  practice  and
0%  stated  that  new  multinational  diagnostic  criteria  were
eeded.46
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  B1,  strong,  in  favor  of  the  statement.
Level  of  agreement:  In  complete  agreement  96%.
In  agreement  with  minor  reservations:  4%.
here  is  insufﬁcient  evidence  for  recommending  a
tandard  group  of  diagnostic  tests  in  all  patients
eeting the  symptom-based  IBS  criteria
ue  to  the  fact  that  IBS  is  a  frequent  illness  in  the  gen-
ral  population,  its  diagnostic  evaluation  is  costly.  Some
tudies  systematically  carrying  out  tests  on  subjects  with
BS  clinical  criteria  have  shown  an  increased  frequency  of
bnormal  results,  but  these  ﬁndings  do  not  modify  the  diag-
osis  or  clinical  behavior  of  the  disease.47--49 A  systematic
eview  of  the  theme  determined  that  the  existing  evidence
s  insufﬁcient  for  recommending  the  routine  use  of  a  bat-
ery  of  diagnostic  tests  in  patients  meeting  the  IBS  clinical
riteria.50
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  C1,  strong,  against  the  intervention.
Level  of  agreement:  In  complete  agreement  100%.
t is  recommendable  to  carry  out  complementary
iagnostic  tests  in  all  patients  that  meet  the
ymptom-based  IBS  clinical  criteria  and  that
resent with  alarm  symptoms,  refractory
ymptoms,  or  risk  factors.  Diagnostic  test  selection
hould be  carried  out  individually,  considering  the
linical  characteristics  of  IBS  and  the  pre-test
ikelihood  of  organic  diseases  (e.g.  celiac  disease,
nﬂammatory bowel  disease,  neoplasias,  etc.)
hen  patients  presenting  with  IBS  clinical  criteria  are  ﬁrst
een,  a  systematic  search  must  be  performed  to  rule  out
ed  ﬂags,  such  as  nocturnal  symptoms,  visible  blood  in
tool,  anemia,  and  signiﬁcant  weight  loss;  physical  exam-
nation  abnormalities,  such  as  palpable  masses;  and  risk
actors,  such  as  a family  history  of  colorectal  cancer,  the
ecent  appearance  of  symptoms,  onset  after  50  years  of
ge,  male  sex,  and  recent  antibiotic  use.51 The  positive
redictive  value  of  alarm  symptoms  is  known  to  be  low
nd  11-15  patients  with  these  ‘‘red  ﬂags’’  need  to  be
tudied  in  order  to  detect  one  patient  with  colorectal
ancer,  inﬂammatory  bowel  disease,  or  malabsorption.52 A
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systematic  review  and  meta-analysis  that  included  15  stud-
ies  and  over  19,000  patients  showed  that  alarm  symptoms
had  low  sensitivity  and  speciﬁcity  for  diagnosing  colorectal
cancer.53 Therefore,  it  is  indispensible  that  test  selection
be  done  individually,  taking  into  account  the  characteris-
tics  and  risk  factors  of  each  patient,  as  well  as  the  local
prevalence  of  the  organic  diseases  that  are  being  looked
for.10,50,54 The  evidence  supporting  this  statement  comes
mainly  from  case  series,  case-control  studies,  and  clinical
guidelines.
GRADE  level  of  evidence  and  strength  of  recommenda-
tion:  C1,  strong,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  96%.
In  agreement  with  minor  reservations:  4%.
It  is  recommendable  to  study  celiac  disease  in
patients with  clinical  criteria  for  IBS  with  diarrhea
and in  those  with  IBS  with  refractory  symptoms
In  some  cases,  IBS  and  CD  can  have  a  similar  clinical  pre-
sentation.  IBS  symptom  prevalence  in  patients  with  CD  is
38%  and  the  risk  for  presenting  with  such  symptoms  is  three
times  as  great  in  those  patients  that  do  not  adhere  to  a
gluten-free  diet.41 CD  prevalence  in  patients  meeting  the
IBS  clinical  criteria  has  been  estimated  to  be  10  times
higher  than  in  the  general  public.50 However,  a  detailed
analysis  of  the  bowel  habit  of  these  patients  is  important,
because  the  prevalence  of  antibodies  associated  with  CD
in  IBS  patients  without  constipation  has  been  found  to  be
similar  to  that  of  asymptomatic  controls.55 For  a  long  time,
CD  was  considered  a  rare  condition  in  Mexico,  but  several
studies  analyzing  the  prevalence  of  antibodies  associated
with  CD  in  different  settings  (university  population,  type  1
diabetes  mellitus  patients,  blood  donors)  suggest  that  the
prevalence  of  this  disease  in  our  country  is  comparable  to
that  found  in  other  populations.56,57 A  study  conducted  on
Mexican  patients  with  IBS  (Rome  III)  found  they  had  a  preva-
lence  of  positive  serology  for  CD  that  was  twice  as  high  as
that  of  healthy  controls  and  that  the  risk  for  presenting  with
CD  conﬁrmed  by  duodenal  biopsy  was  1.5  times  higher.58
They  also  found  that  the  prevalence  of  positive  antibodies
related  to  CD  was  even  higher  in  the  patients  with  IBS-D.
Obviously,  more  and  better  studies  are  required  in  order  to
know  the  real  CD  prevalence  in  the  general  Mexican  pop-
ulation  and  to  distinguish  our  risk  groups,  but  given  the
evidence  we  have  at  the  present  time,  we  recommend  CD
screening  in  patients  with  IBS  clinical  criteria,  especially  in
those  presenting  with  a  predominance  of  diarrhea  that  are
treatment-refractory.
GRADE  level  of  evidence  and  strength  of  recommenda-
tion:  C1,  strong,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  92%.
In  agreement  with  minor  reservations:  4%.
In  complete  disagreement:  4%.
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olonoscopy  should  be  performed  in  patients  with
BS criteria  that  have  risk  factors  for  colon  cancer,
ymptom onset  at  late  stages  of  life,  changes  in
owel habit  pattern,  presence  of  blood  in  stool,
nd in  all  patients  that  do  not  respond  to
reatment.  Colon  biopsy  should  be  performed  in
atients  with  refractory  IBS-D,  even  in  the  absence
f lesions,  to  intentionally  search  for  microscopic
olitis
 systematic  search  should  be  carried  out  in  all  patients
ith  IBS  clinical  criteria  that  present  with  alarm  symptoms,
uch  as  nocturnal  symptoms,  visible  blood  in  stool,  anemia,
nd  signiﬁcant  weight  loss;  physical  examination  abnormal-
ties,  such  as  palpable  masses;  and  risk  factors,  such  as  a
amily  history  of  colorectal  cancer,  recently  appearing  symp-
oms,  onset  after  50  years  of  age,  male  sex,  and  recent
ntibiotic  use. 51 There  is  evidence  of  greater  detection
f  organic  disease  in  patients  presenting  with  IBS  clinical
riteria  with  alarm  symptoms  and  in  patients  with  IBS-D
r  IBS-M  criteria.59 The  American  College  of  Gastroenter-
logy  proposes  the  performance  of  screening  tests  for  the
etection  of  colorectal  cancer  in  patients  above  50  years  of
ge.60 Some  authors  have  suggested  the  intentional  search
or  microscopic  colitis  in  subjects  with  IBS-D  criteria.61,62 At
east  2  studies  conducted  in  Mexico  have  found  an  increased
revalence  of  microscopic  colitis  in  patients  ﬁtting  the  clin-
cal  criteria  of  IBS  and  IBS-D,  in  whom  colon  biopsies  were
ystematically  taken.63,64 It  is  important  that  the  search  for
icroscopic  colitis  in  these  patients  be  carried  out  through
iopsies  of  all  the  segments  of  the  colon,  even  in  the  pres-
nce  of  normal  mucosa  and  when  there  is  no  evidence  of
esions.
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  B1,  strong,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  96%.
In  agreement  with  minor  reservations:  4%.
maging  studies  (barium  enema,  ultrasound,
omputerized  tomography,  magnetic  resonance,
tc.) are  of  little  use  in  patients  with  IBS  symptoms
n the  absence  of  alarm  symptoms  or  comorbidities
adiologic  studies  are  not  necessary  in  patients  that  do  not
resent  with  alarm  symptoms,  but  they  should  be  consid-
red  when  these  symptoms  are  present.  The  choice  of  study
hould  be  individualized  and  determined  by  the  predominant
ymptoms.  Routine  abdominal  ultrasound  in  IBS  patients  is
nnecessary.65 A  recent  review  determined  that  there  is  a
urprising  lack  of  information  on  the  usefulness  of  imaging
tudies  in  IBS.66
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  C1,  strong,  against  the  intervention.
Level  of  agreement:  In  complete  agreement  100%.
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here  is  insufﬁcient  evidence  for  recommending
he routine  use  of  tests  for  detecting  small
ntestinal  bacterial  overgrowth  in  patients  with  IBS
s  mentioned  beforehand,  a  recent  systematic  review  found
hat  the  presence  of  small  intestinal  bacterial  overgrowth  in
BS  patients  varies  widely  and  the  methodology  for  making
his  diagnosis  has  not  been  standardized.27 In  addition,  it
s  not  possible  to  establish  with  certainty  the  cause-and-
ffect  relation  between  symptoms  and  the  presence  of  small
ntestinal  bacterial  overgrowth.67
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  C1,  strong,  against  the  intervention.
Level  of  agreement:  In  complete  agreement  96%.
In  agreement  with  minor  reservations:  4%.
here  is  insufﬁcient  evidence  for  recommending
he routine  use  of  tests  for  detecting  carbohydrate
ntolerance  in  all  IBS  patients
he  same  as  with  small  intestinal  bacterial  overgrowth,
he  prevalence  of  intolerance  to  different  carbohydrates
n  patients  with  IBS  varies  widely  and  the  methodology
or  making  this  diagnosis  has  not  been  standardized,28,68
or  is  it  possible  to  establish  with  certainty  the  cause-
nd-effect  relation  between  symptoms  and  the  presence
f  food  intolerance.29,67 However,  some  experts  state  that
hese  tests  could  be  useful  in  patients  with  refractory  symp-
oms  for  the  purpose  of  carrying  out  a  potentially  beneﬁcial
ietary  intervention.67
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  C1,  strong,  against  the  intervention.
Level  of  agreement:  In  complete  agreement  96%.
In  agreement  with  major  reservations:  4%.
he  questionnaires  for  evaluating  quality  of  life
rovide a  proﬁle  of  state  of  health  and  can  detect
spects of  the  disease  that  require  special
ttention  (e.g.  physical  function,  emotional  role,
ental health).  Symptom  intensity  is  correlated
ith a  negative  impact  on  quality  of  life
ymptom  severity  and  intensity  has  a  consistently  negative
ffect  on  the  quality  of  life  of  these  patients.  Quality  of
ife  is  an  important  measure  in  the  integrated  management
f  the  patient  with  IBS.  Because  it  is  a  functional  disorder
ith  no  organic  marker,  clinical  decisions  are  dependent  on
sking  the  patient  to  evaluate  and  communicate,  through
ifferent  instruments,  how  he  or  she  perceives  his  or  her
tate  of  health.69,70GRADE  level  of  evidence  and  strength  of
ecommendation:  B1,  strong,  against  the  intervention.
Level  of  agreement:  In  complete  agreement  96%.
In  agreement  with  minor  reservations:  4%.
t  present,  there  are  no  biomarkers  for
stablishing  IBS  diagnosis
 biomarker  is  an  objective  biologic  indicator  of  normal
unction,  pathogenic  processes,  or  pharmacologic  responses
o
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o  a therapeutic  intervention.  The  potential  usefulness  of
iomarkers  in  IBS  has  been  studied  in  3  respects:  in  the  dif-
erential  diagnosis  through  the  detection  of  organic  disease
inﬂammatory,  infectious,  or  neoplastic)  manifested  as  non-
peciﬁc  clinical  data  that  substitute  ‘‘limited  study’’;  in  the
iagnosis  made  a  priori  through  the  detection  of  genetic  pat-
erns,  molecular  dysfunction  markers,  and  histologic  data
f  intestinal  permeability  or  low-grade  infection  that  are
een  in  IBS;  and  as  response  predicters.71 Fecal  biomarkers
f  inﬂammation,  such  as  calprotectin,  lactoferrin,  protein
100A12,  polymorphonuclear  elastase,  myeloperoxidase,  M2
yruvate  kinase,  granins,  defensins,  and  matrix  metallopro-
einases,  among  others,  have  been  analyzed  for  establishing
he  differential  diagnosis  of  IBS  with  inﬂammatory  bowel
isease,  but  not  ruling  out  other  diagnostic  possibilities.71--73
ecently,  the  detection  of  anti-CdtB  and  anti-vinculin  serum
ntibodies  has  been  evaluated  and  validated  for  the  diag-
osis  made  a  priori  of  patients  with  IBS-D  with  apparently
ood  results.74 Unfortunately,  these  antibodies  are  not
etectable  in  all  patients  with  IBS-D  and  their  prevalence
n  IBS  patients  is  unknown.  Antibody  expression  depends
n  the  immunologic  condition  of  the  host  and  they  have
nly  been  validated  in  healthy  controls  and  in  patients
ith  CD  and  inﬂammatory  bowel  disease,  without  taking
nto  account  other  possibilities,  such  as  microscopic  col-
tis,  parasitosis,  or  neoplasias.  Only  one  determined  age
ange  was  included  and  the  results  cannot  be  extrapo-
ated  to  all  populations.  Even  though  there  have  been  great
dvances  in  the  development  of  biomarkers  for  the  diag-
osis  of  IBS  in  a  subgroup  of  patients  (e.g.  IBS-D)  and  it
s  clear  that  in  the  future  costs  could  be  reduced  in  the
are  of  these  patients,  contributing  to  the  development  of
rugs,  some  experts  believe  that  they  are  not  yet  ready
or  practical  application.75,76GRADE  level  of  evidence  and
trength  of  recommendation:  B1,  strong,  against  the  inter-
ention.
Level  of  agreement:  In  complete  agreement  92%.
In  agreement  with  minor  reservations:  8%.
rritable bowel syndrome treatment in adults
BS  treatment  should  be  directed  at  the  most
othersome  symptom  or  at  the  pathophysiologic
echanisms  of  the  disease
iven  that  there  is  no  single  medication  for  treating  all
he  patients  with  IBS,  two  types  of  strategies  have  been
ecommended:  directing  treatment  at  the  symptom  that
s  the  most  bothersome  for  the  patient  (pain,  bloating,
onstipation,  diarrhea)  or  at  the  pathophysiologic  mech-
nisms  involved  in  the  production  of  symptoms,  such  as
isceral  hypersensitivity,  motor  alterations,  dysbiosis,  small
ntestinal  bacterial  overgrowth,  ﬂuid  homeostasis,  and
europlasticity.4,77--79GRADE  level  of  evidence  and  strength
f  recommendation:  C2,  weak,  in  favor  of  the  interven-
ion.
Level  of  agreement:  In  complete  agreement  96%.
In  agreement  with  minor  reservations:  4%.
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wThe  Mexican  consensus  on  irritable  bowel  syndrome  
An  adequate  doctor-patient  relationship  has
positive effects  on  overall  improvement,  symptom
improvement, symptom  severity  grade,  and  quality
of life  of  the  patients  with  IBS.  In  addition,  it
reduces the  number  of  medical  consultations  and
increases  patient  satisfaction.  The  doctor-patient
relationship  is  the  most  robust  component  of  the
placebo effect
The  approach  to  IBS  centered  on  the  patient  and  the  effec-
tive  communication  between  the  physician  and  patient
is  associated  with  therapeutic  beneﬁt.  Asking  open  ques-
tions  that  allow  the  patient  to  express  his  or  her  needs,
to  be  actively  listened  to,  and  to  be  shown  empathy
to  strengthen  the  doctor-patient  relationship  are  use-
ful  strategies.80 Calming  the  patient’s  fears  regarding  his
or  her  disease  during  the  initial  medical  visit  has  been
demonstrated  to  signiﬁcantly  reduce  the  self-perception  of
disability.81 An  attentive,  warm,  and  conﬁdence-inspiring
doctor-patient  relationship  has  been  shown  to  have  a
more  intense  positive  effect  on  the  symptoms  of  the
patients.82
GRADE  level  of  evidence  and  strength  of  recommenda-
tion:  C2,  weak,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  100%.
Two  controlled  studies  showed  that  exercise
(20-60 min,  3-5  times  per  week)  produces
improvement in  IBS  symptom  grade,  in
IBS-associated  quality  of  life,  and  that  it  reduces
the risk  for  symptom  worsening
Even  though  the  controlled  studies  are  few,  they  are  good
quality  and  have  demonstrated  improvement  in  IBS  symp-
tom  severity  compared  with  controls.  Exercise  was  capable
of  preventing  symptom  progression  in  the  patients.83 This
improvement  persisted  over  time,  given  that  the  patients
with  an  exercise  plan  maintained  their  symptom  grade  and
quality  of  life  improvement  after  5.2  years.84
GRADE  level  of  evidence  and  strength  of  recommenda-
tion:  C2,  weak,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  88%.
In  agreement  with  minor  reservations:  8%.
In  agreement  with  major  reservations:  4%.
Soluble  ﬁber  ingestion  is  beneﬁcial  in  IBS.  Bran
ingestion does  not  improve  IBS  symptoms
Dietary  ﬁber  supplementation  has  a  long  history  in  the  treat-
ment  of  gastrointestinal  disorders.  However,  caution  has
been  expressed  in  regard  to  its  use,  due  to  the  possibil-
ity  that  ﬁber  can  exacerbate  some  symptoms  in  certain
patients.85,86 The  recent  meta-analysis  of  randomized  and
controlled  studies  by  Moayyedi  et  al.87 showed  the  beneﬁt
of  ﬁber  in  IBS  symptoms,  but  only  in  the  case  of  soluble  ﬁber
and  not  bran.  It  should  be  noted  that  no  signiﬁcant  adverse
effects  were  demonstrated  with  the  use  of  bran.  On  the
other  hand,  no  beneﬁcial  effects  of  linseed  in  relation  to
IBS  have  been  detected,  but  there  is  only  one  quality  study
on  this  topic.87
I
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i
s157
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:
For  soluble  ﬁber  A2,  strong,  in  favor  of  the  intervention.
For  bran  B2,  weak,  against  the  intervention.
Level  of  agreement:  In  complete  agreement  96%.
In  agreement  with  minor  reservations:  4%.
 low-FODMAP  diet  can  improve  overall  symptoms,
he perception  of  bloating,  abdominal  pain,  and
owel habit  in  some  patients  with  IBS
he  fermentable  oligosaccharides,  disaccharides,  monosac-
harides,  and  polyols  are  the  so-called  FODMAPs  and  they
nclude  fructose,  lactose,  fructans,  and  fructooligosaccha-
ides  present  in  common  foods  such  as  fruits,  legumes,
nd  wheat.  After  several  non-controlled  studies  on  dietary
ODMAP  content  and  its  effect  on  IBS  symptoms,88 Halmos
t  al., 89 in  a  randomized  and  blind  study,  demonstrated
mprovement  in  IBS  symptom  grade,  bloating,  pain,  and  ﬂat-
lence  with  the  use  of  a  low-FODMAP  diet.  A  recent  study
onducted  in  Mexico  showed  signiﬁcant  beneﬁcial  results  in
ymptoms  of  patients  on  a  low-FODMAP  diet. 31
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  B1,  weak,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  92%.
In  agreement  with  minor  reservations:  4%.
In  agreement  with  major  reservations:  4%.
 low-FODMAP  diet  reduces  symptoms  in  IBS
atients with  a  self-reported  sensitivity  to  gluten
nd no  celiac  disease,  regardless  of  its  gluten
ontent
any  patients  today  associate  IBS  symptoms  with  the
ngestion  of  products  that  contain  gluten,  suspending
heir  consumption  and  reporting  symptom  improvement.
his  has  been  named  non-celiac  gluten  sensitivity.  Some
tudies  have  shown  that  the  reintroduction  of  gluten  in
atients  with  non-celiac  gluten  sensitivity  that  are  well
ontrolled  with  a  gluten-free  diet  causes  a  reappearance
f  symptoms  that  includes  abdominal  pain  and  fatigue.90
iesiekierski  et  al.91 put  patients  with  IBS  and  this  sensi-
ivity  on  a  low-FODMAP  diet  and  in  a  blind  manner  gave
hem  different  doses  of  gluten  or  placebo.  The  effect
f  gluten  on  symptoms  or  fatigue  could  not  be  demon-
trated.
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  C1,  weak,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  92%.
In  agreement  with  minor  reservations:  8%.
here  is  indirect  evidence  that  the  use  of  bile  acid
equestrants, such  as  cholestyramine,  available  in
exico, produces  symptom  improvement  in  IBS
ith diarrheat  has  been  documented  that  some  patients  with  IBS-D  can
ave  bile  acid  malabsorption.92--95 A  systematic  review  that
ncluded  1,223  patients  with  IBS-D  that  had  a  TauroH-23-(Se)
elena-25-homocholic  acid  (SeHCAT)  test  for  diagnosing  bile
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cid  diarrhea  found  that  26,  32,  and  10%  had  mild,  moder-
te,  and  severe  bile  acid  malabsorption,  respectively.92 This
roup  of  patients  may  beneﬁt  from  bile  acid  sequestrants,
uch  as  cholestyramine  (available  in  Mexico),  colestipol,
olesevelam,  aluminum  hydroxide,  or  obeticholic  acid.94,95
owever,  the  evidence  is  indirect,96 given  that  there  are  no
tudies  that  speciﬁcally  evaluate  the  use  of  cholestyramine
n  IBS-D.
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  B2,  weak,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  92%.
In  agreement  with  minor  reservations:  8%.
ntispasmodic  drugs  are  more  efﬁcacious  than
lacebo for  abdominal  pain  improvement,  overall
mprovement, and  symptom  scores  in  IBS
ntispasmodics  are  a  group  of  medications  that  compete
ith  acetylcholine  in  the  parasympathetic  postganglionic
erve  terminals  or  block  the  calcium  channels,  inhibi-
ing  smooth  muscle  contraction.97 Several  subgroups  of
ntispasmodics  have  been  described5:  1)  direct  relaxing
gents  (mebeverine,  trimebutine);  2)  scopolamine  deriva-
ives  (butylhyoscine,  levsin,  hyoscyamine,  cimetropium);
)  ammonium  derivatives  (that  also  block  calcium  chan-
els,  such  as  otilonium  bromide  and  pinaverium  bromide);
nd  4)  calcium  antagonists  (alverine  citrate,  fenoverine,
ociverine,  pirenzepine,  peppermint).  A  meta-analysis  that
ncluded  29  studies  and  a  total  of  2,333  patients  com-
ared  antispasmodics  with  placebo  and  reported  that
ntispasmodics  as  a  group  were  superior  in  abdominal  pain
mprovement  (58%  of  the  patients  treated  with  antispas-
odics  improved,  compared  with  46%  of  the  control  group,
 <  0.001),  overall  improvement  (57%  of  the  patients  treated
ith  antispasmodics  improved,  compared  with  39%  that
eceived  placebo,  p  <  0.001),  and  in  symptom  score  (37%
f  those  treated  with  antispasmodics  improved,  compared
ith  22%  with  placebo,  p  <  0.01),  with  a  number  necessary  to
reat  (NNT)  of  7,  5,  and  3,  respectively.98 Another  system-
tic  review  and  meta-analysis99 with  23  studies  and  2,585
atients  showed  similar  ﬁndings.  Some  sub-analyses  have
emonstrated  improvement  in  particular  outcomes  with
peciﬁc  antispasmodics:  otilonium  bromide  (reduced  defe-
ation  alterations  and  overall  improvement)  and  pinaverium
romide  (reduced  defecation  discomfort).100 Other  studies
ave  shown  improvement  with  an  antispasmodic  (mebev-
rine)  only  in  non-controlled  studies  with  placebo.99,100
eppermint  oil  is  a  drug  that  has  been  considered  alternative
herapy.  However,  it  has  calcium  antagonist  properties101
nd  has  been  shown  to  be  superior  to  placebo  in  a
ecent  systematic  review  and  meta-analysis  in  pain  improve-
ent  and  overall  symptom  improvement.102 Nevertheless,
he  majority  of  the  studies  have  observed  short-term
mprovement  (6-8  weeks)  and  the  presence  of  side  effects
ncreases  with  use.  There  is  limited  evidence  in  relation
o  long-term  beneﬁt  in  the  main  outcome  measures,  at
east  in  one  study  that  used  otilonium  bromide  for  15
eeks.103
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  A1,  strong,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  100%.
tR.  Carmona-Sánchez  et  al.
he  combination  of  simethicone/dimethicone  with
ntispasmodics  appears  to  improve  abdominal  pain
nd distension
imethicone/simethicone  reduces  the  surface  tension  of
as  bubbles,  causing  their  coalescence.  The  combination  of
imethicone  with  certain  antispasmodics  has  been  shown  to
e  effective,  particularly  in  the  improvement  of  abdominal
ain  and  distension.  In  the  meta-analysis  by  Martínez-
ázquez,  this  same  combination  was  superior  to  placebo
n  overall  symptom  improvement.99 The  combination  of
inaverium  bromide  with  dimethicone  and  alverine  with
imethicone  has  also  been  superior  to  placebo  in  the
mprovement  of  abdominal  distension.99,104,105 The  combi-
ation  of  trimebutine/simethicone  has  not  been  speciﬁcally
valuated  and  so  there  is  no  evidence  for  recommending  its
se.
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  B1,  strong,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  92%.
In  agreement  with  minor  reservations:  8%.
-HT3  receptor  antagonists,  such  as alosetron  and
ndansetron,  improve  the  consistency,  frequency,
nd urgency  of  bowel  movements  in  IBS  with
iarrhea. Alosetron  is  not  available  in  Mexico  and
ts use  is  restricted  due  to  serious  side  effects
edications  that  act  on  the  serotonin  or  5-
ydroxytriptamine  (5-HT)  receptors  owe  their  effect
o  stimulation  or  antagonsim.  The  5-HT3  receptor  antago-
ists  attenuate  bowel  transit  and  increase  ﬂuid  absorption,
hus  improving  IBS-D  symptoms.  A  systematic  review  and
eta-analysis  that  included  11  studies  and  7,216  patients
valuated  the  efﬁcacy  of  this  group  of  medications.106
losetron  proved  to  be  superior  to  placebo  (8  studies,
 =  4,987),  with  a  NNT  of  7  (overall  improvement)  and  8
symptom  persistence),  but  its  use  is  restricted  due  to
erious  side  effects  (number  needed  to  harm  =  10)  that
nclude  severe  constipation  and  ischemic  colitis,  and  it
s  not  available  in  Mexico.101 In  that  review,  cilansetron
lso  showed  improvement  over  placebo  in  overall  symp-
om  reduction  (3  studies,  n =  2,229),  with  a  NNT  of  6
nd  practically  no  side  effects,  but  it  is  not  available
n  Mexico  either.106 Ondansetron,  which  is  available  in
exico,  is  another  5-HT3  antagonist  that  has  been  used
ainly  as  an  antiemetic,  but  there  is  evidence  of  its
sefulness  in  IBS-D.107 A  crossover  and  placebo-controlled
tudy  that  was  conducted  for  5  weeks  in  120  patients  with
BS-D  concluded  that  ondansetron,  titrated  to  response,
mproved  the  consistency  (p  <  0.001),  frequency  (p  =  0.02),
nd  urgency  of  bowel  movements  (p  <  0.001),  in  addition
o  improving  bloating  (p  <  0.001)  in  those  patients  with
BS-D.106
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  B1,  strong,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  92%.
In  agreement  with  minor  reservations:  4%.
In  agreement  with  major  reservations:  4%.
P
c
p
P
l
c
p
e
u
e
(
b
i
f
i
b
i
o
p
t
L
t
c
c
a
L
C
l
m
h
u
S
w
c
S
a
f
t
w
s
a
w
p
t
GRADE  level  of  evidence  and  strength  of  recommenda-
tion:  A1,  strong,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  96%.
In  agreement  with  minor  reservations:  4%.The  Mexican  consensus  on  irritable  bowel  syndrome  
Certain  5-HT4  receptor  agonists  can  improve
symptoms  in  IBS-C.  Tegaserod  has  been  shown  to
be effective,  but  it  should  not  be  used  in  subjects
above 55  years  of  age  or  with  other  cardiovascular
risks
The  5-HT4  receptor  agonists  increase  colon  motility,  as  well
as  the  secretion  of  ﬂuids  and  electrolytes,  and  thus  can
be  useful  in  IBS-C.  Tegaserod  has  shown  beneﬁt  in  overall
improvement  (NNT  =  14),  abdominal  pain,  and  improvement
in  bowel  habit  (NNT  =  20)  in  patients  with  IBS-C.108 In  the
systematic  review  by  Ford,  tegaserod  was  associated  with
less  symptom  persistence  compared  with  placebo,  with  a
NNT  of  10.106 A  sub-analysis  showed  a  greater  effect  in  men
(p  =  0.003).  The  frequency  of  side  effects,  such  as  diarrhea,
had  a  number  necessary  to  harm  of  20.  However,  tegaserod
was  taken  off  most  of  the  international  markets  in  2007,
due  to  a  statistically  higher  frequency  of  adverse  cardiovas-
cular  effects,  such  as  acute  myocardial  infarction,  unstable
angina  pectoris,  cerebrovascular  disease,  and  sudden  death
(0.11  vs  0.01%).  The  hypothetical  interaction  mechanism  is
at  the  5-HT1B/D  receptor  level  in  the  coronary  arterioles,
although  it  was  later  demonstrated  that  tegaserod  did  not
have  that  type  of  agonism.  It  was  reintroduced  in  the  United
States  in  July  2007  under  a  treatment  investigational  new
drug  protocol  for  IBS-C  and  chronic  idiopathic  constipation
in  women  under  the  age  of  55  years  that  had  no  risk  for
certain  cardiovascular  events.  However,  tegaserod  was  not
approved  for  later  use  due  to  the  opinion  of  the  Committee
for  Medicinal  Products  for  Human  Use  that  the  beneﬁt  was
not  superior  to  placebo  and  did  not  outweigh  its  risks.109
In  Mexico,  based  on  the  recommendations  of  a  group  of
experts  from  the  Asociación  Mexicana  de  Gastroenterología,
the  Federal  Commission  Against  Health  Risks  restricted  its
use  to  patients  under  55  years  of  age  and  with  no  cardio-
vascular  risk  (e.g.  hypercholesterolemia,  arrhythmias,  high
blood  pressure,  or  the  use  of  other  medications  that  can
have  an  effect  on  the  QT  segment  of  the  electrocardio-
gram).  Two  other  5-HT4  agonists  available  in  Mexico  are
prucalopride  and  mosapride.  Prucalopride  has  shown  beneﬁt
in  chronic  idiopathic  constipation,  but  has  not  been  evalu-
ated  in  IBS-C.110 There  is  little  evidence  of  the  usefulness  of
mosapride  in  IBS,  but  a  placebo-controlled  pilot  study  with
37  IBS-C  patients  showed  a  reduction  in  the  pain  thresh-
old  and  rectal  perception  in  response  to  the  barostat  test
after  the  administration  of  mosapride.111 Some  drugs  can
have  a  mixed  5-HT4  agonist  and  5-HT3  antagonist  effect,
such  as  cisapride  and  renzapride.  The  former,  similar  to
tegaserod,  was  taken  off  the  majority  of  markets  due  to
a  risk  for  arrhythmias  associated  with  QT  segment  prolon-
gation,  but  it  is  still  available  in  Mexico.  The  latter  is  not
available  in  Mexico  and  there  is  little  evidence  of  beneﬁt  in
IBS.106
GRADE  level  of  evidence  and  strength  of  recommenda-
tion:  B1,  strong,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  96%.
In  agreement  with  minor  reservations:  4%.159
olyethylene  glycol  can  be  useful  for  managing
onstipation  in  IBS,  although  it  is  not  superior  to
lacebo in  pain  or  distension  management
olyethylene  glycol  (PEG)  3350  (or  macrogol)  is  an  osmotic
axative  that  has  been  used  for  the  treatment  of  chronic
onstipation  in  children  and  adults,  including  chronic  idio-
athic  constipation.  Numerous  studies  have  conﬁrmed  its
fﬁcacy  and  safety.  There  is  less  evidence  in  relation  to  its
se  in  IBS-C,  but  a  recent  study  compared  PEG  2250  plus
lectrolytes  vs  placebo  in  a  group  of  patients  with  IBS-C
n  =  68  and  n  =  71,  respectively).  An  increase  in  the  num-
er  of  spontaneous  bowel  movements  (SBMs)  was  observed
n  the  two  groups  from  the  beginning  of  treatment,  but
rom  week  4  the  PEG  group  had  a  statistically  signiﬁcant
ncrease  in  the  number  of  SBMs,  complete  spontaneous
owel  movements,  stool  consistency,  and  straining  sever-
ty.  Nevertheless,  no  improvement  in  the  severity  of  pain
r  abdominal  distension  was  observed  with  respect  to
lacebo.112
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  B1,  strong,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  92%.
In  agreement  with  minor  reservations:  8%.
inaclotide  improves  IBS-C  symptoms,  including
he frequency  of  spontaneous  bowel  movements,
omplete spontaneous  bowel  movements,  stool
onsistency, straining  severity,  bloating,  gas,  and
bdominal  discomfort
inaclotide,  available  in  Mexico,  is  a  guanylate  cyclase
 agonist  that  acts  by  inducing  an  increase  in  cGMP
evels,  causing  accelerated  gastrointestinal  transit,  aug-
ented  intestinal  secretion,  and  a  decrease  in  visceral
ypersensitivity.  Two  pivotal  studies  evaluated  linaclotide
sefulness  in  the  main  symptoms  of  IBS-C.  The  so-called
tudy  31  was  a  double-blind,  placebo-controlled  analysis
ith  crossover  at  12  weeks,  in  which  linaclotide  signiﬁ-
antly  improved  IBS  symptoms,  including  SBM  and  complete
BM  frequency  (p  <  0.0001),  consistency,  strain  severity,  and
bdominal  symptoms  (subjective  bloating,  gas,  and  discom-
ort)  (p  =  0.0003).113 The  second  study,  called  Study  302,  had
he  same  design  and  evaluated  the  same  outcomes  at  26
eeks.114 The  therapeutic  gain  over  placebo  was  17%  and
igniﬁcant  improvement  was  observed  in  all  the  endpoints
nd  visual  symptom  scale  and  quality  of  life  scale  scores,
ith  a  NNT  of  5.1  (overall  response),  7  (pain),  and  4  (com-
lete  SBMs).114 Later  systematic  reviews  have  conﬁrmed
hese  ﬁndings.115
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ubiprostone  is  beneﬁcial  in  overall  improvement,
loating,  pain,  stool  form,  and  frequency  of  bowel
ovements in  patients  with  IBS-C,  but  it  is
urrently unavailable  in  Mexico
ubiprostone  is  a  drug  that  activates  the  type  2  chlorine
hannels,  increasing  gastrointestinal  secretion  and  motility.
ven  though  there  is  greater  experience  in  chronic  idiopathic
onstipation,  its  efﬁcacy  in  IBS-C  is  supported  by  3  studies.
he  ﬁrst  2  show  that  the  drug  was  superior  to  placebo  in
verall  symptom  improvement,  pain,  bloating,  stool  form,
nd  frequency  of  bowel  movements  after  follow-up  at  1  and
 months.116 In  the  third  study,  the  same  cohort  was  treated
or  36  weeks  and  followed  for  52  weeks  and,  again,  lubipros-
one  was  associated  with  a  greater  frequency  of  spontaneous
owel  movements  and  lower  scores  for  pain  and  abdomi-
al  distension,  compared  with  placebo.117 This  drug  is  not
urrently  available  in  Mexico.
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  B1,  strong,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  96%.
In  agreement  with  minor  reservations:  4%.
here  is  insufﬁcient  evidence  for  recommending
he use  of  mesalazine  in  the  treatment  of  IBS
esalazine  (or  mesalamine)  is  a  topical  salicylate  with  an
nknown  action  mechanism.  It  has  been  shown  to  modulate
roinﬂammatory  cytokine  production,  reduce  NF-kappa-b
ranscriptional  activity  and  tumor  necrosis  factor  activa-
ion,  and  inhibit  prostaglandin  and  leukotriene  synthesis.118
he  use  of  mesalazine  may  be  associated  with  improve-
ent  in  low-grade  inﬂammation  of  the  colonic  mucosa  and
hanges  in  the  gut  microbiota  proﬁle.119 However,  these
nti-inﬂammatory  changes  have  not  resulted  in  clinical
mprovement  in  patients  with  IBS.  A  recent  pilot  study
howed  no  signiﬁcant  changes  compared  with  placebo  in
ymptoms  that  included  pain,  bloating,  or  bowel  habit,  nor
n  overall  improvement  or  quality  of  life  in  patients  with
I-IBS.120
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  C2,  weak,  against  the  intervention.
Level  of  agreement:  In  complete  agreement  96%.
In  agreement  with  minor  reservations:  4%.
n  general,  antidepressants,  including  the  tricyclic
ntidepressants  and  selective  serotonin  reuptake
nhibitors, have  been  shown  to  be  effective  in
verall improvement  of  IBS  symptoms
ntidepressants  have  been  evaluated  for  IBS  treatment
ue  to  their  visceral  analgesic  properties  and  have  been
hown  to  be  useful  mainly  in  the  treatment  of  abdomi-
al  pain  and  overall  symptom  imporvement.121 In  a  recent
eta-analysis,98 antidepressants  in  general  were  superior  to
lacebo  for  abdominal  pain  improvement  (p  =  0.03,  NNT  =  5),
verall  improvement  (p  <  0.001,  NNT  =  4),  and  symptom
core  (p  =  0.001,  NNT  =  4).  Two  analyses  by  Ford,  published
tR.  Carmona-Sánchez  et  al.
n  2009  and  2014,  conﬁrmed  the  same  ﬁndings.122,123 The
ricyclic  antidepressants  (e.g.  amitriptyline  [available  in
exico],  imipramine,  desipramine),  as  well  as  the  selective
erotonin  reuptake  inhibitors  (e.g.  sertraline,  citalopram,
aroxetine,  ﬂuoxetine  [all  available  in  Mexico]),  have  shown
his  beneﬁt:  both  groups  are  superior  to  placebo  in  over-
ll  symptom  improvement,  but  the  tricyclic  antidepressants
re  superior  to  the  selective  serotonin  reuptake  inhibitors
n  pain  improvement.98 Their  beneﬁt  is  obtained  4-6  weeks
fter  treatment  and  can  be  limited  by  side  effects.121
he  tricyclic  antidepressants  are  associated  with  constipa-
ion,  somnolence,  and  dry  mouth,  whereas  the  selective
erotonin  reuptake  inhibitors  are  associated  with  nausea
nd  diarrhea,  making  antidepressant  selection  dependent
n  IBS  subgroup,  side  effects,  and  patient  tolerance.
he  selective  norepinephrine  reuptake  inhibitors,  such  as
uloxetine  and  venlafaxine,  have  been  used  for  pain  in
europathy  and  ﬁbromyalgia,  but  there  are  no  studies  in
BS.124
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  A1,  strong,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  96%.
In  agreement  with  minor  reservations:  4%.
ifaximin  produces  overall  improvement  in
on-constipation  IBS,  including  abdominal
istension  and  perception  of  bloating,  as  well  as
oose/watery stool  consistency,  with  no  signiﬁcant
dverse effects
ue  to  the  possible  abnormalities  in  the  gut  microbiota  in
atients  with  IBS,  treatment  with  poorly  absorbable  antibi-
tics  and  luminal  antibiotics  has  the  potential  to  modulate
he  bacterial  composition  of  the  gastrointestinal  tract  and
lter  the  natural  history  of  the  disease  in  the  short  term.
ifaximin  is  a  broad-spectrum,  synthetic,  non-absorbable
ntibiotic  that  has  been  shown  to  be  useful  in  small  intesti-
al  bacterial  overgrowth  and  has  recently  been  evaluated  in
he  management  of  IBS  without  constipation.  Two  random-
zed,  double-blind,  and  placebo-controlled  studies,  called
ARGET  1  and  TARGET  2,  analyzed  a  total  of  1,260  patients
hat  were  given  550  mg  of  rifaximin  three  times  a  day
or  2  weeks,  with  follow-up  at  10  weeks.125,126 In  both
tudies,  rifaximin  was  signiﬁcantly  superior  to  placebo,
n  overall  symptom  improvement  (p  <  0.001),  in  the  per-
eption  of  bloating  (p  <  0.001),  and  in  stool  consistency
mprovement,  with  a  NNT  of  10.2  and  no  signiﬁcant  adverse
ffects.125--127 In  addition,  approximately  half  of  the  patients
ith  IBS  had  a negative  lactulose  breath  test  after  rifax-
min  treatment,  which  was  associated  with  a decrease  in  IBS
ymptom  intensity.27 Effectiveness  in  patients  that  require
etreatment  with  rifaximin  has  been  shown  to  be  simi-
ar  to  that  of  the  ﬁrst  treatment,  even  in  evaluations  of
wo  retreatments,  and  with  a  mean  effect  duration  of  4
onths.128GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  A1,  strong,  for  intervention.
Level  of  agreement:  In  complete  agreement  84%.
In  agreement  with  minor  reservations:  16%.
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Some  probiotics  or  their  combinations  have  been
efﬁcacious as  IBS  treatment  in  overall  symptom
improvement,  as  well  as  in  relief  from  abdominal
pain and  bloating.  However,  it  is  not  known  which
species or  strains  are  the  effective  ones
Changes  in  the  gut  microbiota  of  patients  with  IBS  have
been  described.  The  differences  in  the  composition  of  the
microbiota  are  signiﬁcant  in  patients  with  IBS  compared
with  controls.129 From  23  randomized  and  controlled  stud-
ies  with  different  probiotics  compared  with  placebo,  it  is
concluded  that  probiotics  signiﬁcantly  reduce  the  risk  for
symptom  persistence.  Even  though  the  meta-analyses  sug-
gest  that  probiotics  have  beneﬁcial  effects  on  the  grading
of  overall  symptoms,  as  well  as  on  abdominal  pain,  bloat-
ing,  and  ﬂatulence,  we  still  do  not  know  which  species  or
individual  strains  are  the  most  beneﬁcial.130
GRADE  level  of  evidence  and  strength  of  recommenda-
tion:  B2,  weak,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  92%.
In  agreement  with  minor  reservations:  4%.
In  agreement  with  major  reservations:  4%.
There  is  insufﬁcient  evidence  for  recommending
the use  of  prebiotics  and  synbiotics  in  IBS
The  randomized  and  placebo-controlled  studies  for  eval-
uating  the  effectiveness  of  prebiotics  and  the  studies  on
synbiotics  have  heterogeneous  results  and  therefore  their
efﬁcacy  cannot  be  afﬁrmed.130
GRADE  level  of  evidence  and  strength  of  recommenda-
tion:  D2,  strong,  against  the  intervention.
Level  of  agreement:  In  complete  agreement  100%.
Fecal  microbiota  transplantation  in  IBS  has  been
investigated in  non-controlled  studies  with  results
showing symptom  improvement.  The  use  of  fecal
microbiota transplantation  in  IBS  should  be
restricted to  research  protocols
Fecal  microbiota  transplantation  has  progressed  dramati-
cally  in  the  last  few  years,  together  with  the  developing
knowledge  of  the  gastrointestinal  microbiota.  Differences
have  been  shown  in  the  microbiota  of  individuals  with
IBS  compared  with  healthy  subjects.  However,  we  do  not
know  if  the  administration  of  the  fecal  microbiota  from
healthy  individuals  can  revert  symptoms  in  the  long  term.131
Non-controlled  open  studies  on  the  use  of  fecal  micro-
biota  transplantation  for  IBS  have  shown  cure  or  symptom
improvement  in  52  to  69%  of  cases  and  thus  have  been
reviewed.132 Fecal  microbiota  transplantation  has  poten-
tial  risks,  such  as  communicable  disease  transmission,  and
there  are  reports  of  the  appearance  of  autoimmune  dis-
eases  in  the  long-term  follow-up  after  transplantation.133Therefore,  fecal  microbiota  transplantation  for  the  treat-
ment  of  IBS  should  only  be  carried  out  under  strict  research
protocol.
GRADE  level  of  evidence  and  strength  of  recommenda-
tion:  D2,  weak,  for  intervention.
t161
Level  of  agreement:  In  complete  agreement  96%.
In  agreement  with  minor  reservations:  4%.
n  patients  with  IBS,  the  application  of  true
cupuncture  has  shown  no  signiﬁcant  differences
ompared with  the  application  of  sham
cupuncture,  in  relation  to  symptom  severity  or
uality of  life
omplementary  and  alternative  medicine  is  used  by  an
mportant  number  of  patients  with  functional  gastrointesti-
al  disorders,  corresponding  to  51%  in  patients  with  IBS.134
ue  to  the  safety  of  acupuncture  and  the  fact  that  we  do
ot  have  highly  effective  treatments  for  IBS  improvement,
ts  evaluation  is  relevant.135 There  is  not  a  clear  deﬁnition
s  to  the  meaning  of  placebo  in  acupuncture.  It  usually
nvolves  placing  the  needles  in  zones  that  are  not  consid-
red  the  correct  ones  for  acupuncture  or  not  penetrating
he  skin  with  them  (sham  acupuncture).  Studies  controlled
ith  sham  acupuncture  have  shown  no  beneﬁts  in  relation
o  IBS  symptoms.135
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  D2,  weak,  against  the  intervention.
Level  of  agreement:  In  complete  agreement  87%.
In  agreement  with  minor  reservations:  4%.
In  disagreement  with  minor  reservations:  4%.
In  disagreement  with  major  reservations:  4%.
here  is  not  enough  evidence  to  recommend
oxibustion  for  the  treatment  of  IBS
oxibustion  is  a  technique  associated  with  acupuncture  that
ses  the  burning  of  herbal  preparations  on  acupuncture
oints.  The  systematic  review  and  meta-analysis  of  ran-
omized  and  placebo-controlled  studies  show  inconsistent
esults  and  a  high  risk  for  bias,  thus  its  usefulness  cannot  be
fﬁrmed.136
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  D2,  weak,  against  the  intervention.
Level  of  agreement:  In  complete  agreement  92%.
In  agreement  with  minor  reservations:  4%.
In  complete  disagreement:  4%.
here  is  not  enough  evidence  to  conclude  whether
omeopathy has  any  beneﬁcial  effects  in  IBS
reatment
hree  randomized  and  controlled  studies  conducted  more
han  25  years  ago  showed  very  poor  evidence  due  to  the  low
uality  of  the  reports,  the  high  or  unknown  risk  for  bias,
 short-term  follow-up,  and  sparse  data.  Therefore  there
s  no  evidence  for  afﬁrming  or  ruling  out  the  usefulness  of
omeopathy  in  the  treatment  of  IBS.137
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  D2,  weak,  against  the  intervention.
Level  of  agreement:  In  complete  agreement  92%.
In  agreement  with  minor  reservations:  4%.
In  complete  disagreement:  4%.
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ognitive  behavioral  therapy,  multicomponent
sychological  therapy,  and  dynamic  psychotherapy
dministered  by  qualiﬁed  personnel  have  been
hown to  improve  IBS  symptoms
atients  with  IBS  present  with  higher  levels  of  psychologi-
al  comorbidity  compared  with  healthy  controls.  Therefore,
sychological  therapies  have  been  proposed  as  alternatives
or  IBS  treatment.138,139 Even  though  there  are  randomized
nd  controlled  studies,  the  large  majority  are  biased  due  to
he  impossibility  of  conducting  blind  studies.122
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  C2,  weak,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  100%.
elaxation  therapy,  self-administered  or  minimum
ontact behavioral  therapy,  cognitive  behavioral
herapy administered  online,  stress  management
herapy, multicomponent  psychological  therapy  by
elephone,  and  mindfulness  therapy  have  not  been
hown to  be  effective  in  improving  IBS  symptoms
he  application  of  numerous  psychological  treatments  in
BS  has  been  reported.  Nevertheless,  the  meta-analyses
f  randomized  and  placebo-controlled  studies  have  shown
mportant  heterogeneity  in  the  results,  the  number  of
atients  included  in  the  studies  is  small,  and  it  is  impossible
o  conduct  blind  studies  due  to  the  nature  of  the  treatment.
n  addition,  these  studies  have  the  disadvantage  that  they
o  not  report  adverse  effects,  which  potentially  exist  in  any
reatment.122,140
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  D2,  weak,  against  the  intervention.
Level  of  agreement:  In  complete  agreement  92%.
In  agreement  with  minor  reservations:  4%.
In  complete  disagreement:  4%.
ypnotherapy  performed  by  qualiﬁed  personnel  is
fﬁcacious  in  IBS  treatment
he  meta-analysis  of  5  randomized  studies  showed  the
ffectiveness  of  hypnotherapy  in  the  improvement  of  IBS
ymptoms  compared  with  controls.140
GRADE  level  of  evidence  and  strength  of  recommenda-
ion:  B2,  weak,  in  favor  of  the  intervention.
Level  of  agreement:  In  complete  agreement  92%.
In  agreement  with  minor  reservations:  4%.
In  agreement  with  major  reservations:  4%.
onclusion
BS  is  the  most  frequently  diagnosed  gastrointestinal  dis-
rder  in  daily  practice  and  therefore  it  is  of  the  utmost
mportance  for  the  physician  to  be  up-to-date  in  regard  to  all
he  changes  and  advances  that  have  been  made  in  the  knowl-
dge  of  this  disease  in  the  last  few  years.  We  present  herein
 consensus  review  of  the  most  relevant  progress  in  the
nderstanding  of  this  disorder,  updating  and  complementing
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